Our Focus
BeiGene is focused on creating impactful medicines intended to be accessible to far more patients here in Canada and around the world. We are advancing an innovative, high-value product portfolio primarily targeting blood cancers and solid tumors with the aim of discovering additional first-in-class or best-in-class innovative medicines.
Our Medicines in Canada
BRUKINSA® is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) discovered by BeiGene scientists that is currently being evaluated globally in a broad clinical program as both monotherapy and in combination with other therapies to treat various B-cell malignancies. BRUKINSA® (zanubrutinib) is indicated:
- for the treatment of adults with Waldenström’s Macroglobulinemia (WM).
- for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
- for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.
- for the treatment of adult patients with chronic lymphocytic leukemia (CLL).
- in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory grade 1, 2 or 3a follicular lymphoma (FL) who have received at least 2 prior systemic therapies.
BRUKINSA® was first authorized for use in Canada in March 2021.
Product Monograph
Patient Information
For more information on BRUKINSA® for patients and healthcare professionals please visit https://www.brukinsa.ca.
Our Clinical Trials
We are committed to bringing better treatment options to Canadian patients and are recruiting for clinical trials across a wide range of therapeutic indications, including lymphoma, liver cancers, lung cancers, gastric cancers, breast cancers, and more.
Investigators
We are seeking talented investigators to conduct our clinical trials in Canada. Our aim is to be your sponsor of choice. With your help, we can identify ways to achieve our ultimate vision: to help transform the biotechnology industry, creating impactful medicines that will be accessible and affordable to cancer patients.
BeiGene Canada Fund For Research and Innovation
The BeiGene Canada Fund for Research & Innovation (the BeiGene Canada Fund) is intended to support and enhance research and innovation initiatives related to cancer care in Canada. The fund was designed to leverage financial contributions from other sources including public funding agencies, health charities and other private sector granting sources. For more information on the BeiGene Canada Fund and to apply please click here. To learn more read this article appearing in the Fall 2023 issue of BIOTECanada’s Insights Magazine.
